AR119741A1 - Formas en estado sólido - Google Patents
Formas en estado sólidoInfo
- Publication number
- AR119741A1 AR119741A1 ARP200101439A ARP200101439A AR119741A1 AR 119741 A1 AR119741 A1 AR 119741A1 AR P200101439 A ARP200101439 A AR P200101439A AR P200101439 A ARP200101439 A AR P200101439A AR 119741 A1 AR119741 A1 AR 119741A1
- Authority
- AR
- Argentina
- Prior art keywords
- peaks
- fluoro
- methyl
- compound
- hydrochloride salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851049P | 2019-05-21 | 2019-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119741A1 true AR119741A1 (es) | 2022-01-05 |
Family
ID=71016701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101439A AR119741A1 (es) | 2019-05-21 | 2020-05-21 | Formas en estado sólido |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12252486B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3972972A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2022532790A (cg-RX-API-DMAC10.html) |
| AR (1) | AR119741A1 (cg-RX-API-DMAC10.html) |
| AU (2) | AU2020277398B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3140394A1 (cg-RX-API-DMAC10.html) |
| MX (2) | MX2021014235A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202110836A (cg-RX-API-DMAC10.html) |
| UY (1) | UY38711A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020236948A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| EP3788053B1 (en) | 2018-05-04 | 2024-07-10 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| WO2019232419A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| AU2019284472B2 (en) | 2018-06-11 | 2024-05-30 | Amgen Inc. | KRAS G12C inhibitors for treating cancer |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP7454572B2 (ja) | 2018-11-19 | 2024-03-22 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及びその使用方法 |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
| US12252486B2 (en) | 2019-05-21 | 2025-03-18 | Amgen Inc. | Solid state forms |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US20230183235A1 (en) * | 2020-05-20 | 2023-06-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of amg-510 and process for preparation thereof |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| JP2023551006A (ja) * | 2020-11-26 | 2023-12-06 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 窒素含有複素環誘導体の塩、結晶、並びにその調製方法、及び使用 |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022246069A1 (en) | 2021-05-19 | 2022-11-24 | Teva Pharmaceuticals International Gmbh | Process for preparation of sotorasib and solid state form thereof |
| CN114605406B (zh) * | 2021-09-18 | 2023-05-26 | 都创(上海)医药开发有限公司 | Amg510化合物的晶型及其制备方法和用途 |
| CN115368358A (zh) * | 2022-09-01 | 2022-11-22 | 浙江九洲药业股份有限公司 | 一种Sotorasib新晶型及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201312059D0 (en) | 2013-07-05 | 2013-08-21 | Univ Leuven Kath | Novel GAK modulators |
| MX380928B (es) | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2863873T3 (es) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| UA127968C2 (uk) * | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
| US12252486B2 (en) | 2019-05-21 | 2025-03-18 | Amgen Inc. | Solid state forms |
| EP3972973A1 (en) | 2019-05-21 | 2022-03-30 | Amgen Inc. | Solid state forms |
| EP4700030A3 (en) | 2019-11-14 | 2026-03-18 | Amgen, Inc. | Improved synthesis of kras g12c inhibitor compound |
| CA3161156A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
-
2020
- 2020-05-20 US US17/612,717 patent/US12252486B2/en active Active
- 2020-05-20 WO PCT/US2020/033832 patent/WO2020236948A1/en not_active Ceased
- 2020-05-20 JP JP2021568766A patent/JP2022532790A/ja active Pending
- 2020-05-20 EP EP20731345.3A patent/EP3972972A1/en active Pending
- 2020-05-20 MX MX2021014235A patent/MX2021014235A/es unknown
- 2020-05-20 AU AU2020277398A patent/AU2020277398B2/en active Active
- 2020-05-20 CA CA3140394A patent/CA3140394A1/en active Pending
- 2020-05-21 AR ARP200101439A patent/AR119741A1/es not_active Application Discontinuation
- 2020-05-21 UY UY0001038711A patent/UY38711A/es not_active Application Discontinuation
- 2020-05-21 TW TW109116911A patent/TW202110836A/zh unknown
-
2021
- 2021-11-19 MX MX2025010774A patent/MX2025010774A/es unknown
-
2025
- 2025-05-13 JP JP2025080319A patent/JP2025131597A/ja active Pending
-
2026
- 2026-01-22 AU AU2026200455A patent/AU2026200455A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY38711A (es) | 2020-11-30 |
| AU2026200455A1 (en) | 2026-02-12 |
| JP2025131597A (ja) | 2025-09-09 |
| TW202110836A (zh) | 2021-03-16 |
| JP2022532790A (ja) | 2022-07-19 |
| MX2025010774A (es) | 2025-10-01 |
| AU2020277398B2 (en) | 2026-01-29 |
| US20220235045A1 (en) | 2022-07-28 |
| WO2020236948A1 (en) | 2020-11-26 |
| US12252486B2 (en) | 2025-03-18 |
| CA3140394A1 (en) | 2020-11-26 |
| MX2021014235A (es) | 2022-03-11 |
| AU2020277398A1 (en) | 2021-12-09 |
| EP3972972A1 (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118978A1 (es) | Formas en estado sólido | |
| MX2025010774A (es) | Formas en estado solido | |
| CA3261000A1 (en) | PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS | |
| USD655592S1 (en) | Four-jaw collet chuck | |
| EP3980166A4 (en) | CERAMIC ANION EXCHANGE MATERIALS | |
| NO20043484L (no) | 2-(pyridin-2-ylamino)-pyrido(2,3d)pyrimidin-7-on | |
| IL289456A (en) | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds | |
| EP4512483A3 (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy | |
| PE20142338A1 (es) | Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf | |
| GEP20186841B (en) | Stabilized crystal of tipiracil hydrochloride, and crystallization method for same | |
| EP3736068A4 (en) | REVOLVING TOOL ROD OF A MACHINE TOOL | |
| JP2017512803A5 (cg-RX-API-DMAC10.html) | ||
| IL275839B2 (en) | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist | |
| ES2531088T3 (es) | Sales de clopidogrel y procedimiento de preparación | |
| PH12015502122A1 (en) | Sovaprevir polymorphs and methods of manufacturing thereof | |
| WO2006039250A3 (en) | Chemokine-binding heterocyclic compound salts, and methods of use thereof | |
| GEP20104964B (en) | 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof | |
| IL321492A (en) | Single-cell methods for discovering disease resistance carriers | |
| PL1861389T3 (pl) | Sól, besylan 7-(2-(4-(3-trifluorometylofenylo)-1,2,3,6-tetrahydropiryd-1-ylo)etylo)izochinoliny, jej wytwarzanie i jej zastosowanie w lecznictwie | |
| ZA200801813B (en) | Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one | |
| AR107167A1 (es) | Forma cristalina de picoxistrobina, método de preparación y uso de esta | |
| AR102804A1 (es) | Formas sólidas de un modulador del canal iónico | |
| ZA200302613B (en) | Process for the preparation of bicyclic diketone salts. | |
| FI3740190T3 (fi) | Apomorfiini-palmitiinihappo-yhteiskiteen kiinteä hiukkasmainen kiteinen muoto | |
| AR045362A1 (es) | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |